Nippon Shinyaku Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Nippon Shinyaku Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Nippon Shinyaku Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Nippon Shinyaku Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Nippon Shinyaku Co Ltd (Nippon Shinyaku) develops, manufactures, and commercializes prescribed pharmaceuticals and functional foods. The company offers products for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. The company produces functional foods and ingredients, including preservatives, health food ingredients, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK, and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.
Headquarters
Japan
Address
14, Nishinosho Monguchi-Cho, Kisshoin, Minami-Ku, Kyoto, 601-8550
Website
www.nippon-shinyaku.co.jp
Telephone
81 75 3211111
No of Employees
2,309
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4516 (TYO)
Revenue (2025)
$1.1B
6.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-8.7%
(2025 vs 2024)
Market Cap*
$1.5B
Net Profit Margin (2025)
XYZ
-14.4%
(2025 vs 2024)
* As of and is in US$
Nippon Shinyaku Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Categories: | Hypen |
| Gastrointestinal Drugs | Lunabell LD |
| Cardiovascular Drugs | Lunabell ULD |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed an option agreement with Elixirgen Therapeutics to launch EXG-7001 to treat patients with Duchenne Muscular Dystrophy. |
| 2026 | Contracts/Agreements | In June, the company entered into an agreement with Boston Children's Hospital to develop innovative therapeutic drugs in the field of neurology. |
| 2026 | Asset Purchase | In April, the company acquired the Japan Marketing Authorization for FINTEPLA from UCB Japan. |
Competitor Comparison
| Key Parameters | Nippon Shinyaku Co Ltd | Astellas Pharma Inc | Incyte Corp | Shionogi & Co Ltd | Kyowa Kirin Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | United States of America | Japan | Japan |
| City | Kyoto | Chuo-Ku | Wilmington | Osaka | Chiyoda-Ku |
| State/Province | Kyoto | Tokyo | Delaware | Osaka | Tokyo |
| No. of Employees | 2,309 | 13,643 | 2,844 | 4,959 | 5,161 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shigenobu Maekawa | Chairman | Executive Board | 2021 | 73 |
| Toru Nakai | Director; President | Executive Board | 2021 | 55 |
| Hitomi Kimura | Director; General Manager - Resource Procurement, Production & Assurance Div. | Executive Board | 2021 | 63 |
| Takanori Edamitsu | Director; General Manager-Business Management & Sustainability | Executive Board | 2022 | 63 |
| Hitoshi Ishizawa | Director; General Manager-Functional Food Div | Executive Board | 2021 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer